전체 메뉴 사이트맵

닫기

본문 바로가기

정책동향

홈 > BT정보 > 정책동향

scrap print facebook twitter me2day
글 읽기

Developing New Drugs & Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape

분류 정책동향 > 미국
출처 BIO Ventures for Global Health 조회 2938
자료발간일 2012-03-16 등록일 2012-06-20
첨부파일

Developing_New_Drugs_&_Vaccines_for_Neglected_D...(1983.735 KB)

내용바로가기
평점 평점이 없습니다.

Developing New Drugs & Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape

 


Understanding the research and development (R&D) pipeline for neglected diseases as well as the spectrum of organizations participating in developing these new drugs and vaccines is essential to evaluate the eciency and eectiveness of current R&D models and to inform the design of new programs and initiatives to ll gaps in the neglected disease R&D pipeline. However, this type of analysis has been hindered in part because neglected disease pipelines have not been systematically tracked. Millions of lives could be saved through faster and more effi-cient R&D. It is critical to target our resources and R&D efforts to provide the greatest benet to the world’s poor.


In 2011, BIO Ventures for Global Health (BVGH) released the new and expanded Global Health Primer, a report and online database of compiled drug and vaccine development pipelines for neglected diseases. Using this unique dataset, we explored for the rst time the extent to which dierent types of organizations are participating in drug and vaccine development for a broad range of neglected diseases. BVGH’s new analysis of product developers participating in drug and vaccine development revealed:

 

 

 

........(계속)

 

 

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다

 

 

 

관련기사
국산 수두백신 첫 유럽行… "매주 10만명분 선적" 2018-04-05
백신으로 제1형 당뇨병 해결에 도전? 2018-04-04
박영근 진원생명과학 대표 "CMO 사업 확장…DNA백신 임상 순항 중" 2018-04-04
H7N9 조류독감 인체감염 막는 백신 '등장 눈앞' 2018-03-19
SK케미칼 바이오·제약 사업 진출 30년, ‘신약·백신’서 최초 기록 등 내공 탄탄 2018-03-08
국산 백신 수출길 발목 잡는 식약처 2018-02-28
제넥신-美파마젯, ‘needle-free DNA치료백신’ 개발협력 2018-02-22
SK케미칼, 백신명가 사노피에 ‘세포배양 기술’ 수출 2018-02-14
SK케미칼 "1681억원 규모 백신 기술이전 계약" 2018-02-13
1회 투여 ‘백신’으로 암 세포 사멸 2018-02-12